Evidence map›Paper›PMID 35086621›Full record

Trial reportThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2022

Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia.

L Apriani, R C Koesoemadinata, M L Bastos, D A Wulandari, P Santoso, B Alisjahbana, M E Rutherford, P C Hill, A Benedetti, D Menzies and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Shorter Antitubercular Regimens Versus 9 Months of Isoniazid for Latent Tuberculosis in Children: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Pooled it
  2. Article
  3. The need for effective drugs for TB prevention: set your goals high, and don´t stop till you get there.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

L AprianiTB Working Group, Infectious Disease Research Center, Universitas Padjadjaran, Bandung, Indonesia, Department of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
R C KoesoemadinataTB Working Group, Infectious Disease Research Center, Universitas Padjadjaran, Bandung, Indonesia.
M L BastosOutcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
D A WulandariDepartment of Child Health, Universitas Padjadjaran/Dr Hasan Sadikin General Hospital, Bandung, Indonesia.
P SantosoTB Working Group, Infectious Disease Research Center, Universitas Padjadjaran, Bandung, Indonesia, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Dr Hasan Sadikin General Hospital, Bandung, Indonesia.
B AlisjahbanaTB Working Group, Infectious Disease Research Center, Universitas Padjadjaran, Bandung, Indonesia, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Dr Hasan Sadikin General Hospital, Bandung, Indonesia.
M E RutherfordCentre for International Health, Department of Preventive and Social Medicine, University of Otago, Otago, New Zealand.
P C HillCentre for International Health, Department of Preventive and Social Medicine, University of Otago, Otago, New Zealand.
A BenedettiOutcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, Departments of Epidemiology, Biostatistics and Occupational Health, and Medicine, McGill University, Montreal, QC, Canada.
D MenziesOutcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, Departments of Epidemiology, Biostatistics and Occupational Health, and Medicine, McGill University, Montreal, QC, Canada.
R RuslamiTB Working Group, Infectious Disease Research Center, Universitas Padjadjaran, Bandung, Indonesia, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Padjadjaran University · IDMcGill University Health Centre · CAUniversity of Otago · NZ

Funding

CIHR
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antitubercular AgentsLatent TuberculosisAdultChildHumansIncidenceIndonesiaIsoniazidRifampinAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID35086621
PMCPMC8802562
OpenAlexW4210667056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.